After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...